Enduring Material

Journal Club Discusses JAK inhibitors
View Activity Info
Enter Basic User Info
View Content
Take Post Test
Create Account
Done
View Activity Info
Continue to Enduring Material
 
 
National Psoriasis Foundation

6600 SW 92nd Ave., Suite 300
Portland, OR 97223-7195
General Information
Thursday, January 20, 2022 - Saturday, January 20, 2024
25 minutes
National Psoriasis Foundation
Virtual Conference Room
Psound Bytes CME Podcast
National Psoriasis Foundation
Objectives
  • Increased understanding of the research related to JAK inhibitors
Presentations and Speakers
Journal Club Discusses JAK inhibitors
  • Andrew Blauvelt, MD, MBA - Oregon Medical Research Center
Available Credits/Points
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • The National Psoriasis Foundation designates this enduring material for a maximum of 0.25 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Join us for another Psound Bytes Journal Club episode discussing noteworthy publications in psoriatic disease. In this episode, we discuss recent research and advancements with JAK inhibitors with Dr. Andrew Blauvelt, President, Oregon Medical Research Center in Portland, OR. This program is supported by educational grants from AbbVie, Amgen, Janssen and UCB.
Disclosure Statements
NPF Staff/Planning Committee, has disclosed no relevant financial relationships with commercial interests.
Speakers:
Andrew Blauvelt, MD, MBA has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
  • AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, EcoR1, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron - scientific adviser and/or clinical study investigator - Relationship Has Not Ended
  • Sanofi Genzyme, Sun Pharma, UCB Pharma, and Vibliome - scientific adviser and/or clinical study investigator - Relationship Has Not Ended

Accreditation Statement
  • The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Test Information
0 %
100 %
1/20/2022
Continue to Enduring Material